IMBRUVICA 140 MG 90 CAPS

Ibrutinib is an anticancer drug targeting B-cell malignancies. It is an orally-administered selective and covalent inhibitor of the enzyme Bruton s tyrosine kinase (BTK). Ibrutinib was FDA-approved as a treatment for mantle cell lymphoma and chronic lymphocytic leukemia.